Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + MK-4830 ± lenvatinib vs chemotherapy in advanced ESCC after PD-1/PD-L1 therapy
CTR20230549Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Merck & Co.. Started Mar 2023; status: terminated.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20230549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230549.